Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase Ib Clinical Trial in Multiple Myeloma

Starton Therapeutics Inc. announced the dosing of the first patient in the subcutaneous administration of low-dose lenalidomide (STAR-LLD) Phase Ib clinical trial, which will assess the safety, efficacy, and pharmacokinetics of continuous STAR-LLD for the treatment of multiple myeloma.